Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 1 Published - 14:00 UTC    08:00 EST    02-October-2000      
Issue 172 Next Update - 14:00 UTC 08:00 EST    03-October-2000      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya



















Back To Vidyya FDA Grants First Marketing Approval For Recombinant Fertility Drug To Trigger Ovulation

Another Step Forward In The Treatment Of Infertility

The US Food and Drug Administration (FDA) has granted Serono, Inc. marketing approval for Ovidrel® (choriogonadotropin alfa for injection) for use in infertility treatment, making it the first recombinant human chorionic gonadotropin (hCG) to be approved in the world.

It is the first new recombinant molecule to receive marketing authorization for the treatment of infertility since the approval of recombinant follicle stimulating hormone in 1995 with the approval of Serono's Gonal-F® (follitropin alfa for injection) by the European Agency for the Evaluation of Medicinal Products (EMEA). Serono is planning to launch Ovidrel® in the US by the first quarter of 2001. The company hopes to receive marketing approval from the EMEA for Ovidrel® in the first half of 2001.

Approximately one in ten couples of reproductive age experiences infertility. The most common cause of infertility in women is anovulation, which is brought about by irregularities in the hormones needed to produce and release healthy eggs. Ovidrel® is administered after the stimulation of the growth of follicles or eggs in the ovaries of women being treated for infertility. Ovidrel® is used to trigger ovulation in women with infertility due to anovulation and to promote final maturation of eggs in the ovaries of women undergoing assisted reproductive technologies (ART), such as in-vitro fertilization.

Easy Subcutaneous Administration, Safety and Effectiveness

Ovidrel® is the only hCG in the US to be approved for subcutaneous injection (with a small needle under the skin), making administration convenient. Until now, hCG was extracted from the urine of pregnant women. Urine-derived hCG must be injected intramuscularly, which can often be painful and usually requires the assistance of a partner or healthcare provider.

Clinical studies have shown that Ovidrel® is safe and effective. In comparative trials versus an approved urine-derived hCG, Ovidrel® was associated with a lower incidence of injection site disorders, as described in the full prescribing information. Furthermore, because it is produced by recombinant DNA technology, Ovidrel® has a high level of purity that permits the use of more accurate and precise assays to measure product strength than is possible with urine-derived products.

Serono's Patient-Friendly Fertility Products

"The approval of Ovidrel® by the FDA represents a major milestone in the development of treatments for infertility," said Mike Allen, Executive Vice President, North America, Reproductive Health. "Ovidrel® is a convenient alternative to urine-derived hCGs and enhances the patient-friendly portfolio of infertility products offered by Serono."

Serono's other reproductive health products include Gonal-F® (follitropin alfa for injection), which is subcutaneously administered for ovarian stimulation; Ovidrel®, which is subcutaneously administered to trigger ovulation; and a non-injectable form of progesterone therapy, Crinone® (progesterone gel), which is administered for luteal phase support.

Side effects may occur with the use of fertility drugs. These products should only be prescribed by physicians who are thoroughly familiar with infertility problems and their management. Ovarian hyperstimulation syndrome (OHSS), with or without vascular and pulmonary complications, can occur with the use of fertility drugs. The incidence of uncomplicated, non-severe OHSS in patients using Ovidrel® was 1.7% in ART and 3.0% in ovulation induction. Other side effects in women using Ovidrel® include abdominal pain, injection site reactions, nausea and vomiting. Side effects in women using Gonal-F® include headache, nausea, ovarian cysts and upper respiratory tract infection. Side effects for patients using Crinone® include breast enlargement, constipation, cramps, emotional lability, headache, nausea and somnolence.


Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.